Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin

Clinical Cancer Research

Volumn 2, Issue 4, 1996, Pages 687-693

  Goldwasser, François ^a   Valenti, Monica ^a   Torres, Rosimar ^a   Kohn, Kurt W ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; APHIDICOLIN; CISPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APHIDICOLIN; CAMPTOTHECIN; CISPLATIN; DNA; DNA DAMAGE; DNA, SINGLE-STRANDED; DRUG SYNERGISM; FEMALE; HUMANS; S PHASE; TUMOR CELLS, CULTURED;

EID: 0029867026     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta, 1262: 1-14, 1995.
2. Wang, J. C. Recent studies of DNA topoisomerases. Biochim. Biophys. Acta. 909: 1-9, 1987.
3. Champoux, J. Mechanistic aspects of type-I topoisomerases. In: J. C. Wang and N. R. Cozarelli (eds.), DNA Topology and Its Biological Effects, pp. 217-242. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1990.
4. Pommier, Y., and Tamzawa, A. Mammalian DNA topoisomerase I and its inhibitors In: J. Hickman and T. Tritton (eds.), Cancer Chemotherapy, pp. 214-250. Oxford: Blackwell Scientific Publications Ltd., 1993.
5. Pommier, Y., Leteurtre, F., Fesen, M., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12: 530-542, 1994.
6. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
7. Kjeldsen, E., Svejstrup, J. Q., Gromova, I. I., Alsner, J., and Westergaard, O. Camptothecin inhibits both the DNA cleavage and religation reactions of eukaryotic DNA topoisomerase I. J. Mol. Biol., 228: 1025-1030, 1992.
8. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of Camptothecin analogs as anticancer agents. J. Natl. Cancer Inst., 85: 271-287, 1993.
9. Chen, A. Y., and Liu, L. F. DNA topoisomerases essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
10. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC). 246: 1046-1048, 1994.
11. Abigerges, D., Chabot, G. G., Armand, J. P., Herait, P., Gouyette, A., and Gandia, D. Phase I and pharmacological studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol., 13: 210-221, 1995.
12. Schabel, F. M., Jr., Trader, M. W., Laster, W. R., Jr. Corbett, T. H., and Griswold, D. P., Jr. cis-Dichlorodiammineplatinum(II) chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat. Rep., 63: 1459-1473, 1979.
13. Schwarte, G N., Teicher, B. A., Eder, J. P., Korbut, T., Holden, S. A., Ara, G., and Herman, T. S. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine. Cancer Chemother. Pharmacol., 32: 455-462, 1993.
14. Minagawa, Y., Kigawa, J , Ishihara, H., Itamochi, H., and Terakawa, N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn. J. Cancer Res., 85: 966-971, 1994.
15. Chou, T. C., Motzer, R. J., Tong, V., and Bosl, G. J. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst., 86: 1517-1524, 1994.
16. Cheng, M-F., Chatterjee, S., and Berger, N. A. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regmens. Oncol. Res., 6: 269-279, 1994.
17. Benard, J., Da Silva, J., De Blois, M. C., Boyer, P., Duvillard, P., Chiric, E , and Riou, G. Characterization of a human ovarian adenocarcinoma line, IGROVI, in tissue culture and in nude mice. Cancer Res., 45: 4970-4979, 1985.
18. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
19. Kohn, K. W., Ewig, R. A. G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and crosslinks by alkaline elution. In: E. C. Friedberg and P. C. Hanawalt (eds.), DNA Repair: A Laboratory Manual of Research Procedures, pp. 379-401. New York: Marcel Dekker, Inc., 1981.
20. Bertrand, R., and Pommier, Y. Assessment of DNA damage in mammalian cells by DNA filter elution methodology. In: G. P. Studzinski (ed.), Cell Growth and Apoptosis, Vol. 6, pp. 97-117. Newark, NJ: Oxford University Press, 1995.
21. Perego, P., Capranico, G., Supino, R., and Zunino, F. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Res., 5: 645-649, 1994.
22. Zwelling, L. A., Michaels, S., Schwartz, H., Dobson, P. P., and Kohn, K. W. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res., 41: 640-649, 1981.
23. Reed, E., and Kohn, K. W. Platinum analogues. In: B. A. Chabner and J. M. Colins (eds.), Cancer Chemotherapy. Principles and Practice, pp. 465-490. Philadelphia: J. B. Lippincott, 1992.
24. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. Proteinlinked DNA strand breaks induced in Mammalian cells by camptothecin, an inhibitor of topoisomerase 1. Cancer Res., 49: 5016-5022, 1989.
25. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
26. Hsiang, Y-H., Lihou, M. G., and Liu, L. F. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
27. Bau, R., Gellen, R. W., and Lehovec, S. M. Cristallographic studies on platinum-nucleoside and platinum-nucleotide complexes. J. Clin. Hematol. Oncol., 7: 51-63, 1977.
28. Pinto, A. L., and Lippard, S. J. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta, 780: 167-188, 1985.
29. Plooy, A. C. M., Van Dijk, M., Berends, F., and Lohman, P. H. M. Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Res., 45: 4178-4184, 1985.
30. Teicher, B. A., Hoden, S. A., Kellet, M. J., Shea, T. C., Cucchi, C. A., Rosowski, A., Henner, W. D., and Frei, E., III. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res., 47: 388-393, 1987.
31. Andrews, P. A., Velury, S., Mann, S. C., and Howell, S. B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48: 68-73, 1988.
32. Kelley, S. L., Basu, A., Teicher, B. A , Hacker, M. P., Hamer, D. H., and Lazo, J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science (Washington DC). 241: 1813-1815, 1988.
33. Kasahara, K., Fujiwara, Y., Nishio, K., Ohmori, T., Sugimoto, Y., Komiya, K., Matsuda, T., and Saijo, N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res., 51: 3237-3242, 1991.
34. Eastman, A., and Schulte, N. Enhanced DNA repair as a mechanism of resistance to cis-diamminodichloroplatinum(II). Biochemistry, 27: 4730-4734, 1988.
35. Masuda, H., Ozols, R. F., Lai, G. M., Fojo, A., Rothenberg, M., and Hamilton, T. C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cell lines. Cancer Res., 48: 5713-5716, 1988.
36. Sheibani, N., Jennerwein, M. M., and Eastman, A. DNA repair in cell sensitive and resistant to cis-dichlorodiammineplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry. 28: 3120-3124, 1989.
37. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., and Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest., 94: 703-708, 1994.
38. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
39. Fram, R. J., Rochibaud, N., Bishov, S. D., and Wilson, J. M. Interactions of cis-diamminedichloroplatinum(II) with 1-β-D- Arabinofuranosylcytosine in LoVo colon carcinoma cells. Cancer Res., 47: 3360-3365, 1987.
40. Page, J. D., Husain, I., Sancar, A., and Chaney, S. G. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry, 29: 1016-1024, 1990.
41. Sancar, A. Mechanisms of DNA excision repair. Science (Washington DC), 200: 1954-1956, 1994.
42. Huang, J-C., Hsu, D. S., Kazantsev, A., and Sancar, A. Substrate spectrum of human excinuclease: repair of abasic sites, methylated bases, mismatches, and bulky adducts. Proc. Natl. Acad. Sci. USA, 91: 12213-12217, 1994.
43. Hoeijmakers, J. H. J., and Bootsma, D. Incision for excision. Nature (Lond.), 371: 654-655, 1994.
44. Zhen, W., Evans, M. K., Haggerty, C. M., and Bohr, V. A. Deficient gene specific repair of cisplatin-induced lesions in xeroderma pigmentosum and Fanconi's anemia cell lines. Carcinogenesis, 14: 919-924, 1993.
45. Kessel, D. Effects of camptothecin on RNA synthesis in leukemia cells. Biochim. Biophys. Acta. 246: 225-232, 1971.
46. Bendixen, C., Thomsen, B., Alsner, J., and Westergaard, O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry, 29: 5613-5619, 1990.
47. Mellon, I., Bohr, V. A., Smith, C. A., and Hanawalt, P. C. Preferential DNA repair of an active gene in human cells. Proc. Natl. Acad. Sci. USA, 83: 8878-8882, 1986.
48. Scanlon, K. J., Newman, E. M , Lu, Y., and Priest, D. G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA. 83: 8923-8925, 1986.
49. Swinnen, L. J., Barnes, D. M., Fisher, S G., Albain, K., S., Fisher, R. I. and Erickson, L. C. 1-β-D-Arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res., 49: 1383-1389, 1989.
50. Esaki, T., Nakano, S., Tatsumoto, T., Kuroki-Migita, M., Mitsugi, K., Nakamura, M., and Niho, Y. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-I human squamous carcinoma cell line. Cancer Res., 52: 6501-6506, 1992.
51. Dornish, J. M., Pettersen, E. O., and Oftebro, R. Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidine-2-one. Br. J. Cancer, 56: 273-278, 1987.